Assessment of genomic copy number alterations in breast cancer
The aim of this study was to assess genomic copy number alterations in a panel of breast cancer cell lines. These data were used to identify common aberrations associated with breast cancer, and also to identify aberrations associated with response to therapeutic compounds.
- Type: Cancer Genomics
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples | 
|---|---|---|---|
| EGAD00000000119 | Affymetrix 6.0 | 51 | 
| Publications | Citations | 
|---|---|
| Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 109: 2012 2724-2729 | 302 | 
| HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springerplus 2: 2013 386 | 16 | 
| Modeling precision treatment of breast cancer. Genome Biol 14: 2013 R110 | 181 | 
| A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 32: 2014 1202-1212 | 368 | 
| Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun 7: 2016 12991 | 40 | 
| Gene isoforms as expression-based biomarkers predictive of drug response in vitro. Nat Commun 8: 2017 1126 | 31 | 
| More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. Pharmacol Ther 191: 2018 178-189 | 24 | 
